Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and SRS in TNBC with Brain Metastasis
NCT03483012Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2018
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started May 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03483012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483012.